Scientist Solutions: International Life Science Community By Scientists For Scientists

Thanks to our sponsors who make this site possible

    

Scientist-Solutions

 



Google+

At Scientist Solutions we cherish our role as a trusted source of information for scientists.  We hope that our newly designed site will make it easier than ever for you to access everything we have to offer.   Things may have moved around a little, but rest assured that all the features you enjoyed on our old site (the forums, the protocols, the events, my bench space, blogs)  are still here.  

Our Discussion Forums

Scientist Solutions began as a discussion board for life scientists and that is still one of our core offerings.   If you are looking for the discussion forums, please click "The Forums"  from the navigation bar above or click here.

Protocols and SciEvents

Always on the look out for new ways to help scientists to help each other,  Scientist Solutions introduced a new protocols section and an events section to our site in the past year.   Both have been very popular.   If you haven't yet discovered these listings, we invite you to do so now. 

Our Protocol Finder provides an easily searchable database of protocols that you can use both to find a protocol you need or to share the protocols that you rely on.  Just click "Protocol Finder" from the navigation bar above, or click here.

Our SciEvents section is setting out to be the most comprehensive listing of conferences, seminars, classes and webinars for life scientists on the web.   Search events listings by date, topic or type of event.    You are most welcome to add your own events to our listing too.   Just click SciEvents from the navigation bar above, or click here.

My Bench SpaceMembership Management

Are you looking for how to log in or wondering what happened to your bench space?     On our new site, we have made it much easier for you to manage your account and profile.   After logging in (note that the log in area has moved down the page),  you will see your new member status panel on the right hand side of the home page and every page.    Look here for an overview of your member information and find easy access to your newly remodeled My Bench Space, where you'll be able to edit your account information and preferences and manage your public profile.   Just click "Go to My Bench Space" from your member status panel or click here.

Blogging

Notice that featured blogs are now presented on the home page just below this article.   To read all blogs, just click the "view more" link below the featured blogs.   To create your own blog, go to your My Bench Space pages and click on the "blogs" tab.  To get to My Bench Space, log in then click the "Go to My Bench Space" link in your member status panel (see above) or just click here

Give us your feedback

We understand that it takes a little adjustment time to get used to a new design.  We apologize for any temporary confusion, but hope that once you've familiarized yourself with the new design and features you will be very pleased.   Either way, we would love to hear what you think.  Please share your opinion by clicking the 'contact us'  link at the top right of any page and send us a note or click here.




Latest Member Blogs

Member
Total Posts: 1
7/24/2014
03:21AM
Member
Total Posts: 1
7/1/2014
05:01AM
Member
Total Posts: 4
6/26/2014
03:26PM




Science News Feeds

Click a source to select it and see feeds below

BioScience News
Pharmaceutical News
Biotechnology News
Today's Science News
This Week in Science
Science (Editorial)
Science Now
Nextwave
New York Times
BBC
Bioscreening
Journals
Journal of Biology
Nature
European Journal of Cell Biology
Virology Journal
Science
PNAS
Magazines
New Scientist
The Scientist
Pharmaceutical Business Review
Life Sciences World
Science News

Biotechnology - Google News
Google News
Puma Biotechnology Price Target Raised to $292.00 at Citigroup Inc. (PBYI) - Intercooler

Puma Biotechnology Price Target Raised to $292.00 at Citigroup Inc. (PBYI)
Intercooler
Puma Biotechnology (NASDAQ:PBYI) had its price target increased by Citigroup Inc. from $99.00 to $292.00 in a research report sent to investors on Wednesday morning. The firm currently has a buy rating on the stock. Citigroup Inc. has also modified their ...

and more »
This Year's Hottest Healthcare ETFs - Seeking Alpha (registration)

This Year's Hottest Healthcare ETFs
Seeking Alpha (registration)
The health care sector has significantly outperformed the market over the last 1, 3, and 5-year time frames. Specific industry groups such as pharmaceuticals and biotechnology can often provide a measured boost of additional alpha. The following article ...

and more »
Puma Biotechnology Price Target Raised to $300.00 at Leerink Swann (PBYI) - Intercooler

Puma Biotechnology Price Target Raised to $300.00 at Leerink Swann (PBYI)
Intercooler
Puma Biotechnology (NASDAQ:PBYI) had its target price boosted by Leerink Swann from $144.00 to $300.00 in a report issued on Wednesday. They currently have an outperform rating on the stock. Separately, analysts at Citigroup Inc. reiterated a buy rating ...

and more »
SENS Research Foundation Announces Keynote Speakers for 2014 ... - EIN News (press release)

SENS Research Foundation Announces Keynote Speakers for 2014 ...
EIN News (press release)
"These keynote speakers bring to the Rejuvenation Biotechnology Conference three very diverse perspectives -- the scientific, the investment and the business perspectives," said Mike Kope, CEO of SENS Research Foundation. "Their collective expertise in ...

and more »
Puma Biotechnology (NYSE:PBYI) Stock Triples on Amazing Cancer Drug - Stocks.org

Puma Biotechnology (NYSE:PBYI) Stock Triples on Amazing Cancer Drug
Stocks.org
On Wednesday, Puma Biotechnology (PBYI) had a remarkable rise of 287%, owing mainly to the fact that investors in the healthcare division had ignored the company's stocks (which is unique considering investors are usually inclined towards contemplating ...

and more »
Why Biogen Idec (NASDAQ:BIIB) Shares Roars Again with Puma Biotechnology ... - iStreetWire

Why Biogen Idec (NASDAQ:BIIB) Shares Roars Again with Puma Biotechnology ...
iStreetWire
Shares of Puma Biotechnology (NASDAQ:PBYI) were higher 290% to $232 in trading on Wednesday after the firm declared optimistic top-line results from the Phase 3 trial of its neratinib breast cancer treatment. Experts at Citigroup (C_) are rumoring that the ...

and more »
Puma Biotechnology (PBYI) is in Overbought Territory: What's Next? - Tale of the ... - DigitalJournal.com

Puma Biotechnology (PBYI) is in Overbought Territory: What's Next? - Tale of the ...
DigitalJournal.com
Yet PBYI's high RSI value isn't the only reason for investors to be concerned, as there has been some decidedly negative earnings estimate revisions in Puma Biotechnology's stock as of late. This is especially true when investors dive into some of these ...

and more »
IAM Patent 1000 Guide Distributed to Global Legal Community, Features Myers ... - NCTechNews (press release)

IAM Patent 1000 Guide Distributed to Global Legal Community, Features Myers ...
NCTechNews (press release)
RALEIGH, N.C. -- Myers Bigel Sibley & Sajovec, P.A. (Myers Bigel), the largest independent patent law firm in North Carolina, is proud to announce that attorneys Alice Bonnen, Ph.D. (biotechnology) and Mitch Bigel (electronics/computer) are featured in the ...

News buzz- World Wrestling Entertainment, Inc.(NYSE:WWE), Demand Media ... - Techsonian (press release)

News buzz- World Wrestling Entertainment, Inc.(NYSE:WWE), Demand Media ...
Techsonian (press release)
Prana Biotechnology Limited (ADR) (PRAN) reported that its Phase 2 REACH2HD clinical trial investigating PBT2 as a cure for Huntington disease met its primary safety endpoint and achieved statistically significant improvement in a measure of executive ...

Puma Biotechnology (PBYI) is in Overbought Territory: Whats Next? - Zacks.com

Puma Biotechnology (PBYI) is in Overbought Territory: Whats Next?
Zacks.com
Yet PBYI's high RSI value isn't the only reason for investors to be concerned, as there has been some decidedly negative earnings estimate revisions in Puma Biotechnology's stock as of late. This is especially true when investors dive into some of these ...

and more »